1. Adrian HJ, Dorr U, Bach D, Bihl H (1993) Biodistribution of111In-pentetreotide and dosimetric considerations with respect to somatostatin receptor expressing tumor burden. Horm Metab Res [Suppl] 27:18?23
2. Anker-Lugtenburg PJ van den, Krenning EP, Oei HY, Gerrits CHJ, Vanhagen PM, Reubi J-C, Lamberts SWJ, Löwenberg B (1994) The role of somatostatin receptor scintigraphy (SRS) in the initial staging of malignant lymphoma. J Nucl Med 35:132P
3. Arndt JW, Lamers CBHW, Jansen JBMJ, Pauwels EKJ (1993) De waarde van somatostatine receptor scintigrafie (111In-Octreoscan) bij patienten met gastrointestinale en pancreas apudoma's. Nucl Geneeskd Bull 15:69?70
4. Bajc M, Ingvar C, Persson B, Tibblin S, Karlsson S-E, Edenbradt L, Palmer J (1993) Dynamic octreotide scintigraphy in neuroendocrine tumours. Eur J Nucl Med 20:843
5. Bakker WH, Krenning EP, Breeman WAP, Koper JW, Kooij PPM, Reubi JC, Klijn JG, Visser TJ, Docter R, Lamberts SWJ (1990) Receptor scintigraphy with a radioiodinated somatostatin analogue: radiolabeling, purification, biologic activity, and in vivo application in animals. J Nucl Med 31:1501?1509